These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 18382853)

  • 21. Early cytokine production risk stratifies trauma patients for multiple organ failure.
    Jastrow KM; Gonzalez EA; McGuire MF; Suliburk JW; Kozar RA; Iyengar S; Motschall DA; McKinley BA; Moore FA; Mercer DW
    J Am Coll Surg; 2009 Sep; 209(3):320-31. PubMed ID: 19717036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease.
    Ko HH; Bressler B
    Expert Rev Gastroenterol Hepatol; 2007 Oct; 1(1):29-39. PubMed ID: 19072431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toward experimental assessment of receptor occupancy: TGN1412 revisited.
    Waibler Z; Sender LY; Kamp C; Müller-Berghaus J; Liedert B; Schneider CK; Löwer J; Kalinke U
    J Allergy Clin Immunol; 2008 Nov; 122(5):890-2. PubMed ID: 18805577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The TeGenero incident and the Duff Report conclusions: a series of unfortunate events or an avoidable event?
    Horvath CJ; Milton MN
    Toxicol Pathol; 2009 Apr; 37(3):372-83. PubMed ID: 19244218
    [No Abstract]   [Full Text] [Related]  

  • 25. Final report of the safety assessment of Alcohol Denat., including SD Alcohol 3-A, SD Alcohol 30, SD Alcohol 39, SD Alcohol 39-B, SD Alcohol 39-C, SD Alcohol 40, SD Alcohol 40-B, and SD Alcohol 40-C, and the denaturants, Quassin, Brucine Sulfate/Brucine, and Denatonium Benzoate.
    Cosmetic Ingredient Review Expert Panel
    Int J Toxicol; 2008; 27 Suppl 1():1-43. PubMed ID: 18569160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dissociation of efficacy and cytokine release mediated by an Fc-modified anti-CD3 mAb in a chronic experimental autoimmune encephalomyelitis model.
    Belmar NA; Lombardo JR; Chao DT; Li O; Ma X; Pong-Afar M; Law DA; Starling GC
    J Neuroimmunol; 2009 Jul; 212(1-2):65-73. PubMed ID: 19477024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z; Kala P
    Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of methionine oxidation on the binding of human IgG1 to Fc Rn and Fc gamma receptors.
    Bertolotti-Ciarlet A; Wang W; Lownes R; Pristatsky P; Fang Y; McKelvey T; Li Y; Li Y; Drummond J; Prueksaritanont T; Vlasak J
    Mol Immunol; 2009 May; 46(8-9):1878-82. PubMed ID: 19269032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alemtuzumab: new indication. First line treatment of chronic lymphocytic leukaemia: continue to use oral chlorambucil.
    Prescrire Int; 2009 Apr; 18(100):60. PubMed ID: 19585719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alternative strategies for toxicity testing of species-specific biopharmaceuticals.
    Bussiere JL; Martin P; Horner M; Couch J; Flaherty M; Andrews L; Beyer J; Horvath C
    Int J Toxicol; 2009; 28(3):230-53. PubMed ID: 19546261
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Etiology and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia.
    Cheson BD
    Clin Adv Hematol Oncol; 2009 Apr; 7(4):263-71. PubMed ID: 19521331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety evaluation to support First-In-Man investigations II: toxicology studies.
    Baldrick P
    Regul Toxicol Pharmacol; 2008 Jul; 51(2):237-43. PubMed ID: 18501490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Whole-blood culture is a valid low-cost method to measure monocytic cytokines - a comparison of cytokine production in cultures of human whole-blood, mononuclear cells and monocytes.
    Damsgaard CT; Lauritzen L; Calder PC; Kjaer TM; Frøkiaer H
    J Immunol Methods; 2009 Jan; 340(2):95-101. PubMed ID: 19000693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytokine release assays: current practices and future directions.
    Finco D; Grimaldi C; Fort M; Walker M; Kiessling A; Wolf B; Salcedo T; Faggioni R; Schneider A; Ibraghimov A; Scesney S; Serna D; Prell R; Stebbings R; Narayanan PK
    Cytokine; 2014 Apr; 66(2):143-55. PubMed ID: 24412476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pre-clinical strategies and safety issues in developing therapeutic monoclonal antibodies.
    Chamberlain P
    N Biotechnol; 2011 Sep; 28(5):481-8. PubMed ID: 21473945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Applicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope.
    Kizhedath A; Wilkinson S; Glassey J
    Arch Toxicol; 2017 Apr; 91(4):1595-1612. PubMed ID: 27766364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines.
    Tamimoto Y; Horiuchi T; Tsukamoto H; Otsuka J; Mitoma H; Kimoto Y; Nakashima H; Muta K; Abe Y; Kiyohara C; Ueda A; Nagasawa K; Yoshizawa S; Shimoda T; Harada M
    Rheumatology (Oxford); 2008 Jun; 47(6):821-7. PubMed ID: 18397955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination with cytokines in autoimmune diseases.
    Delavallée L; Assier E; Denys A; Falgarone G; Zagury JF; Muller S; Bessis N; Boissier MC
    Ann Med; 2008; 40(5):343-51. PubMed ID: 18484346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Considerations for the development of therapeutic monoclonal antibodies.
    Swann PG; Tolnay M; Muthukkumar S; Shapiro MA; Rellahan BL; Clouse KA
    Curr Opin Immunol; 2008 Aug; 20(4):493-9. PubMed ID: 18586093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is an in vitro whole blood cytokine assay useful to detect the potential risk of severe infusion reaction of monoclonal antibody pharmaceuticals?
    Iwata Y; Harada A; Hara T; Kubo C; Inoue T; Tabo M; Ploix C; Manigold T; Hinton H; Mishima M
    J Toxicol Sci; 2016; 41(4):523-31. PubMed ID: 27432238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.